Compare GeneDx Holdings Corp (WGS) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Wipro Limited — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Wipro Limited trades at $1.71 (market cap $16.22B). The key difference: Wipro Limited is far larger — about 8× GeneDx Holdings Corp's market cap, and Wipro Limited pays a 5.19% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Wipro Limited for 41 Days on average.
| WGS | WIT | |
|---|---|---|
Market Cap | $2.02B | $16.22B |
Volume | 734,640 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $167.51 | $3.06 |
52-Week Low | $34.51 | $1.61 |
Typical Hold Time | 19 Days | 41 Days |
Enterprise Value | $2.05B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
WIT trades at $1.715, up 2.69% today, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with recent earnings misses but maintains solid profitability and cash flow. Recent news highlights AI-driven productivity gains and strategic partnerships, though revenue growth remains subdued. Analyst sentiment is cautious with a majority hold rating.
The outlook is balanced: valuation appears reasonable with a P/E of 12.78, and strong cash flow supports stability. However, earnings misses and bearish technicals pose near-term risks. Investment appeal hinges on execution of AI initiatives and revenue acceleration against competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
